{"generic":"Cinoxacin","drugs":["Cinobac","Cinoxacin"],"mono":{"0":{"id":"124439-s-0","title":"Generic Names","mono":"Cinoxacin"},"1":{"id":"124439-s-1","title":"Dosing and Indications","sub":[{"id":"124439-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Urinary tract infectious disease:<\/b> 500 mg ORALLY twice a day or 250 mg ORALLY 4 times a day for 7 to 14 days<\/li><li><b>Urinary tract infectious disease; Prophylaxis:<\/b> 250 mg ORALLY once daily at bedtime<\/li><\/ul>"},{"id":"124439-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy have not been established in children"},{"id":"124439-s-1-6","title":"Dose Adjustments","mono":"<b>renal impairment:<\/b> CrCl 50-80 mL\/min, 250 mg 3 times a day; CrCl 20-50 mL\/min, 250 mg twice a day; CrCl less than 20 mL\/min, 250 mg once a day"},{"id":"124439-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Urinary tract infectious disease<\/li><li>Urinary tract infectious disease; Prophylaxis<\/li><\/ul>"}]},"3":{"id":"124439-s-3","title":"Contraindications\/Warnings","sub":[{"id":"124439-s-3-9","title":"Contraindications","mono":"hypersensitivity to cinoxacin products\/quinolones<br\/>"},{"id":"124439-s-3-10","title":"Precautions","mono":"<ul><li>patients with known or suspected CNS disorders<\/li><li>risk for phototoxicity<\/li><\/ul>"},{"id":"124439-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"124439-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"124439-s-4","title":"Drug Interactions","sub":{"1":{"id":"124439-s-4-14","title":"Major","mono":"<ul>Clozapine (established)<\/ul>"}}},"5":{"id":"124439-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea, Nausea, Vomiting<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Dizziness, Headache<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Hypersensitivity reaction (Severe) (rare)<br\/>"},"6":{"id":"124439-s-6","title":"Drug Name Info","sub":{"0":{"id":"124439-s-6-17","title":"US Trade Names","mono":"Cinobac<br\/>"},"2":{"id":"124439-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Non-Fluorinated Quinolone<\/li><\/ul>"},"3":{"id":"124439-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"124439-s-7","title":"Mechanism Of Action","mono":"Systemic: Bactericidal in the urine and acts by inhibition of bacterial DNA replication.  <br\/>"},"8":{"id":"124439-s-8","title":"Pharmacokinetics","sub":[{"id":"124439-s-8-23","title":"Absorption","mono":"Systemic: Rapid and almost complete; food delays absorption <br\/>"},{"id":"124439-s-8-24","title":"Distribution","mono":"Systemic: Vd: 0.24 to 0.26 L\/kg <br\/>"},{"id":"124439-s-8-25","title":"Metabolism","mono":"Systemic: Hepatic: 30 to 40% <br\/>"},{"id":"124439-s-8-26","title":"Excretion","mono":"Systemic: Renal: 97%, 50 to 75% unchanged <br\/>"},{"id":"124439-s-8-27","title":"Elimination Half Life","mono":"Systemic: 1.5 to 3.5 h <br\/>"}]},"9":{"id":"124439-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>take with or without food<br\/>"},"10":{"id":"124439-s-10","title":"Monitoring","mono":"fever, CBC, symptomatic improvement of UTI<br\/>"},"12":{"id":"124439-s-12","title":"Toxicology","sub":[{"id":"124439-s-12-31","title":"Clinical Effects","mono":"<b>QUINOLONE DERIVATIVES<\/b><br\/>QUINOLONE DERIVATIVES have similar toxicity, but differ in the incidence and extent of these effects. NALIDIXIC ACID - OVERDOSE - Nausea, vomiting, lethargy, toxic psychosis, seizures, increased intracranial pressure, hyperglycemia, or metabolic acidosis may occur in overdose.  Visual disturbances and photophobia have also been reported. ADVERSE EFFECTS: Photosensitivity, rash, nausea and vomiting, diarrhea, dizziness, headache, somnolence, prolonged QT interval, metabolic acidosis, hemolytic anemia, anaphylaxis, traumatic or non-traumatic rupture of tendon, coma, peripheral neuropathy, and seizure.<br\/>"},{"id":"124439-s-12-32","title":"Treatment","mono":"<b>QUINOLONE DERIVATIVES<\/b><br\/><ul><li>Decontamination: Activated charcoal.<\/li><li>Support: There is no specific antidote.  Treatment is symptomatic and supportive.<\/li><li>Seizure: IV benzodiazepines, barbiturates.<\/li><li>Hypotensive episode: IV NaCl 0.9%, dopamine, norepinephrine.<\/li><li>Crystalluria: Adequate hydration may prevent crystalluria.<\/li><li>Monitoring of patient: Monitor vital signs, serum electrolytes and fluid status in symptomatic patients. Monitor patients for respiratory and CNS depression and seizures.<\/li><\/ul>"},{"id":"124439-s-12-33","title":"Range of Toxicity","mono":"<b>QUINOLONE DERIVATIVES<\/b><br\/>TOXICITY: Seizures have been reported in children receiving 50 mg\/kg\/day or greater of nalidixic acid. Seizures may also be seen with therapeutic doses. A 19-year-old developed coma, hypotonia, and severe metabolic acidosis after taking as much as 28 g of nalidixic acid. The patient survived following supportive therapy. THERAPEUTIC DOSE: ADULTS - 500 mg to 1 g orally 4 times daily for 1 to 2 weeks; CHILDREN - 33 to 55 mg\/kg\/day orally in 4 divided doses for 1 to 2 weeks.<br\/>"}]},"13":{"id":"124439-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause phototoxicity. Advise patient to use sunscreen and avoid tanning beds.<\/li><li>This drug may cause diarrhea, nausea, vomiting, dizziness, or headache.<\/li><\/ul>"}}}